Literature DB >> 27135418

Medication use and potentially high-risk prescribing in older patients hospitalized for diabetes: a missed opportunity to improve care?

G E Caughey1, J D Barratt1, S Shakib2,3, A Kemp-Casey1,4, E E Roughead1.   

Abstract

AIMS: To examine the appropriateness of medicine use and potentially high-risk prescribing before and after hospitalization for diabetes.
METHODS: A retrospective cohort study of patients hospitalized for diabetes was conducted using administrative data from the Australian Government Department of Veterans' Affairs for the period between 1 January 2012 and 31 December 2012. The appropriateness of medicine use and potentially high-risk prescribing, including hyper-polypharmacy and associated treatment conflicts, were examined for the 120-day periods before and after hospitalization.
RESULTS: A total of 876 patients were hospitalized for a diabetes-related complication. Of these, 25% were not dispensed an antidiabetic medicine 4 months before hospitalization and 25% had not had their HbA1c levels measured in the preceding 6 months. The use of antidiabetic medicines increased to 85% after hospitalization, with a 25.6% relative increase (95% CI 10.9-42.1) in the proportion of those dispensed insulin. The prevalence of high-risk prescribing before hospital admission was high; 70% had > 10 medicines dispensed, a third had at least one treatment conflict and half were dispensed a potentially inappropriate medicine. The use of long-acting sulphonylureas and corticosteroids had relative decreases of 46.0% (95% CI 17.0-64.9) and 29.9% (95% CI 8.8-46.0), respectively. Few changes in other high-risk prescribing patterns were observed after discharge.
CONCLUSIONS: This study has identified poor medication-related care and, in particular, high-risk-prescribing in people subsequently hospitalized for diabetes. While diabetes medicine use improved after hospitalization, there was little change in potentially inappropriate medicine use, which suggests that an opportunity to improve medication use in this older vulnerable population has been missed.
© 2016 Diabetes UK.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27135418     DOI: 10.1111/dme.13148

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  5 in total

1.  Prevalence and factors associated with polypharmacy: a systematic review and Meta-analysis.

Authors:  Mahin Delara; Lauren Murray; Behnaz Jafari; Anees Bahji; Zahra Goodarzi; Julia Kirkham; Mohammad Chowdhury; Dallas P Seitz
Journal:  BMC Geriatr       Date:  2022-07-19       Impact factor: 4.070

2.  Study protocol for assessing the user acceptance, safety and efficacy of a tablet-based workflow and decision support system with incorporated basal insulin algorithm for glycaemic management in participants with type 2 diabetes receiving home health care: A single-centre, open-label, uncontrolled proof-of-concept study.

Authors:  Angela Libiseller; Julia Kopanz; Katharina M Lichtenegger; Julia K Mader; Thomas Truskaller; Bettina Lackner; Felix Aberer; Marlene Pandis; Johanna Reinisch-Gratzer; Gisela C Ambrosch; Frank Sinner; Thomas R Pieber; Klaus Donsa
Journal:  Contemp Clin Trials Commun       Date:  2020-07-17

3.  Challenges and Strategies for Diabetes Management in Community-Living Older Adults.

Authors:  Alan J Sinclair; Ahmed H Abdelhafiz
Journal:  Diabetes Spectr       Date:  2020-08

4.  Potentially inappropriate medications according to STOPP-J criteria and risks of hospitalization and mortality in elderly patients receiving home-based medical services.

Authors:  Chi-Hsien Huang; Hiroyuki Umegaki; Yuuki Watanabe; Hiroko Kamitani; Atushi Asai; Shigeru Kanda; Hideki Nomura; Masafumi Kuzuya
Journal:  PLoS One       Date:  2019-02-08       Impact factor: 3.240

Review 5.  Potentially inappropriate prescribing for adults living with diabetes mellitus: a scoping review.

Authors:  Mohammed Biset Ayalew; M Joy Spark; Frances Quirk; Gudrun Dieberg
Journal:  Int J Clin Pharm       Date:  2022-07-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.